全球血浆分离市场规模、份额、趋势和成长分析报告（2026-2034年）

预计血浆分馏市场将从 2025 年的 441.8 亿美元成长到 2034 年的 965.2 亿美元，2026 年至 2034 年的复合年增长率为 9.07%。

全球血浆分离市场正稳定成长，主要受用于治疗免疫力缺乏、出血性疾病和神经系统疾病的血浆衍生疗法需求不断增长的推动。血浆分离技术可将血浆分离成其主要蛋白质成分，例如免疫球蛋白、白蛋白和凝血因子。慢性病和罕见病患疾病的上升也显着推动了市场需求。

关键成长要素包括生物技术的进步、血浆采集基础设施的改善以及人们对血浆疗法的认识不断提高。政府对血浆捐献计画的支持以及开发中国家医疗保健系统的扩展进一步提升了市场前景。持续的研发工作正在改善纯化技术并提高生产效率。

展望未来，随着治疗应用范围的扩大和全球医疗保健支出的成长，市场预计将持续成长。它将在新兴经济体中发挥更关键的作用，扩大病患的用药途径。分馏技术的创新和监管规范的统一有望进一步增强该行业的长期发展前景。

目录

第一章：引言

第二章执行摘要

第三章 市场变数、趋势与框架

• 市场谱系展望
• 渗透率和成长前景分析
• 价值链分析
• 法律规范
  • 标准与合规性
  • 监管影响分析
• 市场动态
  • 市场驱动因素
  • 市场限制因素
  • 市场机会
  • 市场挑战
• 波特五力分析
• PESTLE分析

第四章 全球血浆分离市场：依产品划分

• 市场分析、洞察与预测
• 白蛋白
• 免疫球蛋白（静脉注射免疫球蛋白、皮下注射免疫球蛋白及其他免疫球蛋白）
• 凝血因子（因子VIII、因子IX、血管性血友病因子、凝血酶原复合物浓缩物、纤维蛋白原浓缩物等）
• 蛋白酶抑制剂
• 其他的

第五章：全球血浆分离市场：依方法划分

• 市场分析、洞察与预测
• 离心分离
• 深度过滤
• 层析法
• 其他的

第六章 全球血浆分离市场：依应用划分

• 市场分析、洞察与预测
• 神经病学
• 血液学
• 肿瘤学
• 免疫学
• 肺科
• 其他的

第七章：全球血浆分离市场：依最终用途划分

• 市场分析、洞察与预测
• 医院和诊所
• 临床研究
• 其他的

第八章 全球血浆分离市场：依地区划分

• 区域分析
• 北美市场分析、洞察与预测
  • 我们
  • 加拿大
  • 墨西哥
• 欧洲市场分析、洞察与预测
  • 英国
  • 法国
  • 德国
  • 义大利
  • 俄罗斯
  • 其他欧洲国家
• 亚太市场分析、洞察与预测
  • 印度
  • 日本
  • 韩国
  • 澳洲
  • 东南亚
  • 其他亚太国家
• 拉丁美洲市场分析、洞察与预测
  • 巴西
  • 阿根廷
  • 秘鲁
  • 智利
  • 其他拉丁美洲国家
• 中东和非洲市场分析、洞察与预测
  • 沙乌地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中东和非洲国家

第九章 竞争情势

• 最新趋势
• 公司分类
• 供应链和销售管道合作伙伴（根据现有资讯）
• 市场占有率和市场定位分析（基于现有资讯）
• 供应商情况（基于现有资讯）
• 策略规划

第十章：公司简介

• 主要公司的市占率分析
• 公司简介
  • Grifols SA
  • CSL Limited
  • Takeda Pharmaceutical Company Limited
  • Octapharma AG
  • Kedrion SPA
  • LFB SA
  • Biotest AG
  • Sanquin
  • Bio Products Laboratory Ltd
  • Intas Pharmaceuticals Ltd

The Plasma Fractionation Market size is expected to reach USD 96.52 Billion in 2034 from USD 44.18 Billion (2025) growing at a CAGR of 9.07% during 2026-2034.

The Global Plasma Fractionation Market has witnessed steady growth driven by increasing demand for plasma-derived therapies used in treating immune deficiencies, bleeding disorders, and neurological conditions. Plasma fractionation involves separating plasma into its key protein components such as immunoglobulins, albumin, and clotting factors. Rising prevalence of chronic and rare diseases has significantly boosted market demand.

Major growth drivers include advancements in biotechnology, improved plasma collection infrastructure, and growing awareness of plasma-based treatments. Government support for plasma donation programs and expansion of healthcare systems in developing countries further enhance market prospects. Continuous R&D efforts are improving purification techniques and production efficiency.

Looking forward, the market is expected to grow as therapeutic applications expand and global healthcare spending increases. Emerging economies will play a crucial role due to expanding patient access. Innovations in fractionation technology and regulatory harmonization will further strengthen the industry's long-term outlook.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Product

• Albumin
• ImmunoglobulinsA ((Intravenous immunoglobulins, Subcutaneous immunoglobulins, Other immunoglobulins))
• Coagulation FactorsA (Factor VIII, Factor IX, VON Willebrand Factor, Prothrombin Complex Concentrates, Fibrinogen Concentrates, Others)
• Protease inhibitors
• Others

By Method

• Centrifugation
• Depth Filtration
• Chromatography
• Others

By Application

• Neurology
• Hematology
• Oncology
• Immunology
• Pulmonology
• Others

By End-use

• Hospitals & Clinics
• Clinical Research
• Others

COMPANIES PROFILED

• Grifols SA, CSL Limited, Takeda Pharmaceutical Company Limited, Octapharma AG, Kedrion SpA, LFB SA, Biotest AG, Sanquin, Bio Products Laboratory Ltd, Intas Pharmaceuticals Ltd

We can customise the report as per your requriements

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL PLASMA FRACTIONATION MARKET: BY PRODUCT 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Product
• 4.2. Albumin Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. ImmunoglobulinsA ((Intravenous immunoglobulins, Subcutaneous immunoglobulins, Other immunoglobulins)) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Coagulation FactorsA (Factor VIII, Factor IX, VON Willebrand Factor, Prothrombin Complex Concentrates, Fibrinogen Concentrates, Others) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Protease inhibitors Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.6. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL PLASMA FRACTIONATION MARKET: BY METHOD 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Method
• 5.2. Centrifugation Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Depth Filtration Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Chromatography Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL PLASMA FRACTIONATION MARKET: BY APPLICATION 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Application
• 6.2. Neurology Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Hematology Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Oncology Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.5. Immunology Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.6. Pulmonology Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.7. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL PLASMA FRACTIONATION MARKET: BY END-USE 2022-2034 (USD MN)

• 7.1. Market Analysis, Insights and Forecast End-use
• 7.2. Hospitals & Clinics Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.3. Clinical Research Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL PLASMA FRACTIONATION MARKET: BY REGION 2022-2034(USD MN)

• 8.1. Regional Outlook
• 8.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.2.1 By Product
  • 8.2.2 By Method
  • 8.2.3 By Application
  • 8.2.4 By End-use
  • 8.2.5 United States
  • 8.2.6 Canada
  • 8.2.7 Mexico
• 8.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.3.1 By Product
  • 8.3.2 By Method
  • 8.3.3 By Application
  • 8.3.4 By End-use
  • 8.3.5 United Kingdom
  • 8.3.6 France
  • 8.3.7 Germany
  • 8.3.8 Italy
  • 8.3.9 Russia
  • 8.3.10 Rest Of Europe
• 8.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.4.1 By Product
  • 8.4.2 By Method
  • 8.4.3 By Application
  • 8.4.4 By End-use
  • 8.4.5 India
  • 8.4.6 Japan
  • 8.4.7 South Korea
  • 8.4.8 Australia
  • 8.4.9 South East Asia
  • 8.4.10 Rest Of Asia Pacific
• 8.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.5.1 By Product
  • 8.5.2 By Method
  • 8.5.3 By Application
  • 8.5.4 By End-use
  • 8.5.5 Brazil
  • 8.5.6 Argentina
  • 8.5.7 Peru
  • 8.5.8 Chile
  • 8.5.9 South East Asia
  • 8.5.10 Rest of Latin America
• 8.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.6.1 By Product
  • 8.6.2 By Method
  • 8.6.3 By Application
  • 8.6.4 By End-use
  • 8.6.5 Saudi Arabia
  • 8.6.6 UAE
  • 8.6.7 Israel
  • 8.6.8 South Africa
  • 8.6.9 Rest of the Middle East And Africa

Chapter 9. COMPETITIVE LANDSCAPE

• 9.1. Recent Developments
• 9.2. Company Categorization
• 9.3. Supply Chain & Channel Partners (based on availability)
• 9.4. Market Share & Positioning Analysis (based on availability)
• 9.5. Vendor Landscape (based on availability)
• 9.6. Strategy Mapping

Chapter 10. COMPANY PROFILES OF GLOBAL PLASMA FRACTIONATION INDUSTRY

• 10.1. Top Companies Market Share Analysis
• 10.2. Company Profiles
  • 10.2.1 Grifols S.A
  • 10.2.2 CSL Limited
  • 10.2.3 Takeda Pharmaceutical Company Limited
  • 10.2.4 Octapharma AG
  • 10.2.5 Kedrion S.P.A
  • 10.2.6 LFB S.A
  • 10.2.7 Biotest AG
  • 10.2.8 Sanquin
  • 10.2.9 Bio Products Laboratory Ltd
  • 10.2.10 Intas Pharmaceuticals Ltd